Transarterial Therapies for Hepatocellular Carcinoma

被引:63
|
作者
Lanza, Ezio [1 ]
Donadon, Matteo [2 ]
Poretti, Dario [1 ]
Pedicini, Vittorio [1 ]
Tramarin, Marco [1 ]
Roncalli, Massimo [3 ]
Rhee, Hyungjin [4 ]
Park, Young Nyun [5 ]
Torzilli, Guido [2 ]
机构
[1] Humanitas Univ, Humanitas Res Hosp IRCCS, Dept Intervent Radiol, Milan, Italy
[2] Humanitas Univ, Humanitas Res Hosp IRCCS, Dept Hepatobiliary & Gen Surg, Via Manzoni 56, IT-20089 Milan, Italy
[3] Humanitas Univ, Humanitas Res Hosp IRCCS, Dept Pathol, Milan, Italy
[4] Yonsei Univ, Coll Med, Dept Radiol, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea
关键词
Predictors of response after TAE and TACE for HCC; TAE and TACE for HCC; HEPATIC ARTERIAL CHEMOEMBOLIZATION; STEM-CELLS; RADIOEMBOLIZATION; EMBOLIZATION; EXPRESSION; SURVIVAL;
D O I
10.1159/000449347
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. Summary: The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results. The present work describes the role of transarterial therapies for HCC and focuses on the different Western and Eastern approaches to the study of response predictors. Key Messages: Recent refinements in interventional radiology techniques and in HCC patient selection have facilitated better local control of the disease. The molecular profiling of HCC to predict the response to TACE and TAE will greatly help clinicians identify the optimum therapy. Copyright (C) 2016 S. Karger AG, Basel
引用
收藏
页码:27 / 33
页数:7
相关论文
共 50 条
  • [1] Transarterial Therapies for Hepatocellular Carcinoma
    Makramalla, Abouelmagd
    Itri, Jason N.
    Choe, Kyuran Ann
    Ristagno, Ross L.
    SEMINARS IN ROENTGENOLOGY, 2016, 51 (02) : 95 - 105
  • [2] Transarterial therapies for hepatocellular carcinoma
    Sangro, Bruno
    D'Avola, Delia
    Inarrairaegui, Mercedes
    Prieto, Jesus
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (07) : 1057 - 1073
  • [3] Locoregional Transarterial Therapies for Hepatocellular Carcinoma: Transarterial Chemoembolization and Radioembolization
    Inarrairaegui, Mercedes
    D'Avola, Delia
    Sangro, Bruno
    VISZERALMEDIZIN, 2013, 29 (02): : 92 - 102
  • [4] Current research status of transarterial therapies for hepatocellular carcinoma
    Zhou, Mao-Ting
    Zhang, Peng
    Mao, Qi
    Wei, Xiao-Qin
    Yang, Lin
    Zhang, Xiao-Ming
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (09)
  • [5] Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardization
    Tsochatzis, Emmanuel A.
    Meyer, Tim
    O'Beirne, James
    Burroughs, Andrew K.
    JOURNAL OF HEPATOLOGY, 2013, 58 (01) : 194 - 194
  • [6] Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma
    Hulin, Anne
    Stocco, Jeanick
    Bouattour, Mohamed
    CLINICAL PHARMACOKINETICS, 2019, 58 (08) : 983 - 1014
  • [7] Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
    Perfahl, H.
    Jain, H., V
    Joshi, T.
    Horger, M.
    Malek, N.
    Bitzer, M.
    Reuss, M.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [8] Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma
    Anne Hulin
    Jeanick Stocco
    Mohamed Bouattour
    Clinical Pharmacokinetics, 2019, 58 : 983 - 1014
  • [9] Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
    H. Perfahl
    H. V. Jain
    T. Joshi
    M. Horger
    N. Malek
    M. Bitzer
    M. Reuss
    Scientific Reports, 10
  • [10] Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis
    Patel, Mikin V.
    Davies, Heather
    Williams, Abimbola O.
    Bromilow, Tom
    Baker, Hannah
    Mealing, Stuart
    Holmes, Hayden
    Anderson, Nicholas
    Ahmed, Osman
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1061 - 1071